suppli chain
walgreen guidanc revis underscor larg pharmaci creat equal
import anchor network perfect storm industri headwind translat
revis outlook mirror headwind address earlier year
lower brand inflat declin front-end comp deterior pharmaci
front end fundament emphas align payor
prefer network critic success factor increasingli vertic
fiscal could see downsid continu reimburs
headwind structur chang new rebat rule come play
manag commentari suggest reimburs headwind normal
fiscal expect lower rate usual implement januari
spill fiscal moreov guidanc take account
potenti chang drug price reimburs rate propos rebat rule
implement januari pose anoth risk earn view
read through suppli chain
neutral headwind discuss walgreen call alreadi
mostli reflect guidanc fact lower estim
walgreen use retail segment guidanc proxi
declin earn power exhibit compar walgreen result us retail
segment could mean march quarter swing factor includ
softer cold flu season weak season gift store script
growth analysi suggest experi similar trend would
repres headwind rel ep estim
context consensu guidanc
neg distributor view pharmaci reimburs pressur
lead indic suggest risk distributor sell side margin earn
year unfold see note detail
part wbad purchas consortium see increment step
gener procur in-lin trend walgreen
 distribut unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
experienc like augment sell side pressur
fiscal ep unchang in-line model updat
lower fiscal ebit estim billion y/i vs
billion previous softer environ somewhat off-set share buyback
billion complet first half year increment
million buyback remaind year manag guid ep
compar impli guidanc mid point rang
lower fiscal ep estim fiscal
model ebit billion y/i billion previous
manag expect resum growth oper ep
estim y/i manag guidanc flat constant
currenc ep growth
right multipl share
analyz histor year forward ev/ebitda multipl
see exhibit appli ev/ebitda multipl base case
year averag compani exclud peak multipl period
stefano pessina took helm multipl also normal trough year
like walgreen perform dampen disput
express script base case price target base
ev/ebitda multipl appli updat calendar
ebitda estim billion bull case valuat bear
case valuat
deriv base case scenario assign ev/ebitda multipl
adj ebitda
ev/ebitda multipl appli adjust ebitda
ev/ebitda multipl appli adjust ebitda
ebitda assum script growth front store comp
synergi bp pharmaci reimburs pressur fulli off-set
exclud histor peak multipl view unlik absent
accret strateg acquisit and/or subsid amazon threat
use six year averag multipl exclud period
multipl compress due combin compani specif issu
disput express script market
ev/ebitda multipl adj ebitda
ev/ebitda multipl adj ebitda
ebitda assum script growth flat front store comp
synergi bp pharmaci reimburs pressur partial
off-set wbad cost save assign multipl reflect year average
multipl exclud peak multipl view
unlik absent accret strateg acquisit and/or subsid
ev/ebitda multipl appli adjust ebitda
ev/ebitda multipl appli adjust ebitda
ebitda assum script growth front store comp synergi
wbad cost save off-set pharmaci reimburs pressur
assign multipl repres trough multipl amazon/pillpack
acquisit announc
retail pharmaci chain us well
boot pharmaci allianc drug
distribut europ
expect benefit
eas year-over-year comparison lap
part contract loss contribut
fred anoth round cost
reduct underli fundament still
walgreen balanc sheet deploy
capit well strateg
option eg lh potenti
reposit portfolio asset chang
strategi provid roadmap futur
growth potenti catalyst share
updat rad/fr integr
sg leverag fail materi
risk achiev price
walgreen abl drive market
store integr drive higher
expect save
extrapol walgreen march quarter
adj us retail ebit tailwind
y/i declin
q/q growth
retail ebit tailwind
account
overal y/i
q/q declin
y/i declin
q/q declin
vs ms estimate y/i q/q
assumpt analysi includ
report comp script growth y/i report
brand inflat
pharmaci reimburs pressur bp realiz bp
store benefit revenu growth report
front end comp report bp due de-emphasize tobacco exclud analysi
morgan stanley estim compani data
note million
updat estim price
morgan stanley estim compani data
retail metric watch
exhibit retail metric
compani data estim
look back histor ev/ebitda multipl
exhibit timelin vs multipl expansion/contract
script translat
share loss
win lead
bloomberg estim
valuat methodolog risk
ew price target deriv assign ev/ebitda multipl
adj ebitda assign multipl reflect year average wba/cv multipl
exclud peak multipl view unlik absent accret
strateg acquisit and/or subsid amazon threat risk target
includ market script growth store integr drive higher
expect potenti increas cost save
ow pt base case price target base sotp analysi assign
ev/ebitda multipl retail ev/ebitda multipl pharmaci servic
price-to-earnings multipl health benefit also assum million deal
synergi risk target includ plan buy new model
amazon headlin risk manag care consolid lost pbm contract
